Every 10-Q that GIVBUX INC (GBUX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow GBUX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GBUX filings page.
GIVBUX, INC. (GBUX) reports that for the six months ended June 30, 2026 it generated $90,170 of revenue, down from $121,826 a year earlier, and incurred a net loss of $755,170, a sharp improvement from a $6,631,650 loss in the prior-year period. Total assets were only $99,956 against total liabilities of $5,173,258, leaving a stockholders’ deficit of $5,073,302 and a working capital deficit of the same magnitude. Cash stood at $17,976, while current obligations include $1,526,661 of convertible notes and $973,428 of Level 3 derivative liabilities. Management states there is substantial doubt about the company’s ability to continue as a going concern and plans to seek additional equity and debt financing. As of September 8, 2026, common shares outstanding had risen to 476,022,153, and the company highlights penny stock, illiquidity, and dilution risks. Management also discloses material weaknesses in internal control, including lack of an audit committee and inadequate segregation of duties, and confirms disclosure controls were not effective.
GivBux Inc. reported another quarterly loss and flagged substantial doubt about its ability to continue as a going concern. For the quarter ended March 31, 2026, revenue was $55,906, down modestly from $66,023 a year earlier, but gross profit improved to $25,980 from $10,873 as cost of revenue fell.
Operating expenses more than doubled to $468,577, largely from higher general and administrative and professional fees tied to financing activities, driving a loss from operations of $442,597. After a non‑cash gain of $338,965 from the change in fair value of derivative liabilities and other items, net loss narrowed to $207,076 versus $526,819 a year ago.
The balance sheet remains highly stressed: total assets were only $119,922 against current liabilities of $5,011,645, leaving a stockholders’ deficit of $4,891,723 and a working capital deficit of $4,893,911. Management disclosed significant use of high‑discount convertible notes and warrants, with many notes in default and derivative liabilities of $997,271. The company increased authorized common shares first to 350 million and then, after quarter‑end, to 750 million to provide sufficient stock for conversions, signaling heavy potential dilution.
GivBux Inc. (GBUX) reported Q3 2025 results showing a sharp swing to a net gain of $3.34 million, compared with a net loss of $0.22 million a year earlier. This was driven almost entirely by a $4.24 million non‑cash gain from the change in fair value of derivative liabilities, while core operations remained loss‑making.
Revenue for Q3 2025 fell to $89,988 from $257,920 as the company reduced beta‑test related promotions; nine‑month revenue declined to $211,814 from $330,319. For the first nine months of 2025, GivBux recorded a net loss of $3.29 million, similar to the prior‑year loss.
The balance sheet is very weak: at September 30, 2025, GivBux had $208,696 in total assets, $5.60 million in liabilities, a working capital deficit of $5.41 million, cash of only $82,383, and an accumulated deficit of $33.39 million. Management discloses substantial doubt about the company’s ability to continue as a going concern, citing dependence on raising additional equity or debt financing.